A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

Overview

About this study

The purpose of this study is to evaluate the safety, tolerability, and preliminary effectiveness of ZB131 in patients with solid tumors where prevalence of CSP expression is high. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Diagnosis of histologically or cytologically confirmed advanced solid tumors.

Dose Escalation Stage:

  • Patients with solid tumors (excluding melanoma and hepatocellular CR) who have failed all available therapies or are not eligible for standard of care (SOC).

Expansion Stage:

  • Cohort A: Advanced or Metastatic Pancreatic Cancer (pancreatic ductal; adenocarcinoma) who have failed or are not eligible for SOC.
  • Cohort B: Advanced or Metastatic Ovarian Cancer of the serous type (ovarian serous adenocarcinoma; ovarian serous cystadenocarcinoma) who have failed or are not eligible for SOC.
  • Cohort C: Advanced or Metastatic Biliary Cancer (intrahepatic, extrahepatic, gallbladder) who have failed or are not eligible for SOC.
  • Eastern Cooperative Oncology Group (ECOG) status of 0-1.
  • Measurable disease per RECIST as assessed by local site investigator/radiologists; lesions situated in previous irradiated areas are considered measurable if progression has been demonstrated in such lesions.
  • Locally advanced, recurrent, or metastatic neoplastic disease that has failed to respond to standard therapy, is not curable by currently available local therapies, or for whom no appropriate therapies are available (based on the judgement of the Investigator.
  • Life expectancy of ≥ 3 months in the judgement of the Investigator.
  • Adequate hematologic function based on the following:
    • Absolute neutrophil count ≥1.5 x 10^9/L;
    • Platelet count ≥100 x 10^9/L c. Hemoglobin ≥ 9.0 g/dL.
  • Adequate coagulation parameters based on the following:
    • Prothrombin Time-International Normalized Ratio/partial thromboplastin time (PT-INR/PTT) < 1.5 x ULN, unless coumarin derivatives are used;
    • Activated partial thromboplastin time (APTT) < 1.25 x ULN (therapeutic anticoagulation therapy is allowed, if this treatment can be interrupted for a biopsy as judged by the Investigator).
  • Adequate hepatic function based on the following:
    • Total bilirubin <1.5 × upper limit of normal (ULN) (unless elevated due to Gilbert's syndrome [≤ 3.0 × ULN]) and/or isolated elevations of indirect bilirubin are eligible for study participation;
    • Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5 × ULN for patients with known hepatic metastases);
    • For Expansion cohorts, Albumin >- 3 g/dL.
  • Adequate renal function based on serum creatinine clearance ≥60 mL/min (normal to mild renal impairment) as determined by Cockcroft-Gault equation in the Dose Escalation Stage.
    • For the Dose Expansion Stage, serum creatinine clearance ≥ 45 mL/min (moderate renal impairment) may be included.
  • Female patients of childbearing potential must have a negative pregnancy test. For women of childbearing potential (WCBP), defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally post-menopausal for at least 12 consecutive months for women > 55 years of age, a negative urine pregnancy test (UPT) must be obtained within 72 hours before first treatment. WCBP should be placed on effective birth control directly after testing negative for pregnancy; if not, then WCBP should have a UPT on Day 1 of every dosing cycle, prior to drug administration. Any positive or indeterminant UPT result must be confirmed by serum pregnancy test.
  • Female patients of childbearing potential must use a highly effective mode of contraception or abstain from heterosexual activity for the duration of the trial and for 120 days following the last dose of study medication. Highly effective contraception includes oral hormonal contraceptives, hormonal contraceptive implant, injection or patch, intrauterine device, or complete abstinence from sexual intercourse.
  • Male patients must agree to use highly effective contraception. Sexually active males who have not had a vasectomy, and whose partner is reproductively capable, must agree to abstain from sexual intercourse or use barrier contraception from Screening through 120 days after their last dose of study treatment.
  • Ability to adhere to the study visit schedule and all protocol requirements.

Exclusion Criteria:

  • Major surgery within 4 weeks prior to Screening.
  • Prior radiotherapy within 2 weeks of start of study treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids for their radiation therapy, and no history of radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-central nervous system disease.
  • Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal therapy, targeted therapy, or investigational agents within five half-lives or four weeks, whichever is shorter, prior to administration of the first dose of study treatment.
  • Active CNS metastases; however, patients who have undergone radiation and/or surgery for the treatment of CNS metastases, who are neurologically stable, and who are no longer taking pharmacologic doses of corticosteroids are eligible; patients with leptomeningeal metastases are not eligible.
  • Primary CNS malignancy.
  • Evidence of metastatic ileus on CT.
  • Moderate or clinically significant ascites.
  • Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry.
  • Known active Infection with human immunodeficiency virus (HIV), hepatitis B (HBV), or hepatitis C virus (HCV):
    • Patients who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrollment.
      • Note: Patients should remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy post completion of study intervention.
    • Hepatitis B screening tests are not required unless: 1. Known history of HBV infection, 2. Mandated by local health authority. Patients with a history of hepatitis C virus infection are eligible if HCV viral load is undetectable at Screening.
      • Note: Patients must have completed curative antiviral therapy at least 4 weeks prior to enrollment.
    • Hepatitis C screening tests are not required unless: 1. Known history of HCV infection, 2. Mandated by local health authority.
  • Requiring immunosuppressive therapy.
  • Ongoing systemic bacterial, fungal, or viral infections at Screening.
    • NOTE: Patients on antimicrobial, antifungal, or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met.
  • Received a live vaccine within 6 weeks of first dose of study drug.
  • Received a COVID-19 vaccine less than 1 week prior to dosing (Visit 2 / Day 1) and/or plans to receive a COVID-19 vaccine during the study period.
  • Baseline QT interval corrected with Fridericia's method (QTcF) > 480 ms.
    • NOTE: Criterion does not apply to patients with a right or left bundle branch block.
  • Female patients who are pregnant or breastfeeding.
  • Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia.
  • History of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
  • History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to Screening.
    • NOTE: Current atrial fibrillation that is on treatment and under control is permitted.
  • Unstable or severe uncontrolled medical condition (e.g., unstable cardiac function, unstable pulmonary condition including pneumonitis and/or interstitial lung disease, uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the Investigator's judgment, increase the risk to the patient associated with his or her participation in the study.

Eligibility last updated 2/23/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Hani Babiker, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Mojun Zhu, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mitesh Borad, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20533785

Mayo Clinic Footer